Nuvation Bio Inc
Company Profile
Business description
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.
Contact
1500 Broadway
Suite 1401
New YorkNY10036
USAT: +1 332 208-6102
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
278
Stocks News & Analysis
stocks
Palantir earnings: AI leadership intact; valuation still causes heartburn
stocks
As Nvidia crosses $5 trillion, 5 charts on the unstoppable tech rally
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,090.50 | 83.50 | -0.91% |
| CAC 40 | 8,067.53 | 42.26 | -0.52% |
| DAX 40 | 23,949.11 | 183.30 | -0.76% |
| Dow JONES (US) | 47,085.24 | 251.44 | -0.53% |
| FTSE 100 | 9,714.96 | 13.59 | 0.14% |
| HKSE | 25,952.40 | 205.96 | -0.79% |
| NASDAQ | 23,348.64 | 486.09 | -2.04% |
| Nikkei 225 | 51,497.20 | 914.14 | -1.74% |
| NZX 50 Index | 13,588.29 | 17.67 | -0.13% |
| S&P 500 | 6,771.55 | 80.42 | -1.17% |
| S&P/ASX 200 | 8,809.80 | 72.90 | -0.82% |
| SSE Composite Index | 3,960.19 | 16.33 | -0.41% |